Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved..
SIGNIFICANCE: The United States is in an acceleration phase of the COVID-19 pandemic. Currently there is no known effective therapy or vaccine for treatment of SARS-CoV-2, highlighting urgency around identifying effective therapies.
OBJECTIVE: The purpose of this study was to evaluate the role of hydroxychloroquine therapy alone and in combination with azithromycin in hospitalized patients positive for COVID-19.
DESIGN: Multi-center retrospective observational study.
SETTING: The Henry Ford Health System (HFHS) in Southeast Michigan: large six hospital integrated health system; the largest of hospitals is an 802-bed quaternary academic teaching hospital in urban Detroit, Michigan.
PARTICIPANTS: Consecutive patients hospitalized with a COVID-related admission in the health system from March 10, 2020 to May 2, 2020 were included. Only the first admission was included for patients with multiple admissions. All patients evaluated were 18 years of age and older and were treated as inpatients for at least 48h unless expired within 24h.
EXPOSURE: Receipt of hydroxychloroquine alone, hydroxychloroquine in combination with azithromycin, azithromycin alone, or neither.
MAIN OUTCOME: The primary outcome was in-hospital mortality.
RESULTS: Of 2,541 patients, with a median total hospitalization time of 6 days (IQR: 4-10 days), median age was 64 years (IQR:53-76 years), 51% male, 56% African American, with median time to follow-up of 28.5 days (IQR:3-53). Overall in-hospital mortality was 18.1% (95% CI:16.6%-19.7%); by treatment: hydroxychloroquine+azithromycin, 157/783 (20.1% [95% CI: 17.3%-23.0%]), hydroxychloroquine alone, 162/1202 (13.5% [95% CI: 11.6%-15.5%]), azithromycin alone, 33/147 (22.4% [95% CI: 16.0%-30.1%]), and neither drug, 108/409 (26.4% [95% CI: 22.2%-31.0%]). Primary cause of mortality was respiratory failure (88%); no patient had documented torsades de pointes. From Cox regression modeling, predictors of mortality were age>65 years (HR:2.6 [95% CI:1.9-3.3]), white race (HR:1.7 [95% CI:1.4-2.1]), CKD (HR:1.7 [95%CI:1.4-2.1]), reduced O2 saturation level on admission (HR:1.5 [95%CI:1.1-2.1]), and ventilator use during admission (HR: 2.2 [95%CI:1.4-3.3]). Hydroxychloroquine provided a 66% hazard ratio reduction, and hydroxychloroquine+azithromycin 71% compared to neither treatment (p<0.001).
CONCLUSIONS AND RELEVANCE: In this multi-hospital assessment, when controlling for COVID-19 risk factors, treatment with hydroxychloroquine alone and in combination with azithromycin was associated with reduction in COVID-19 associated mortality. Prospective trials are needed to examine this impact.
| Errataetall: |
CommentIn: Int J Infect Dis. 2020 Oct;99:38-39. - PMID 32738483 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:97 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 97(2020) vom: 01. Aug., Seite 396-403 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arshad, Samia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4QWG6N8QKH |
|---|
| Anmerkungen: |
Date Completed 30.07.2020 Date Revised 11.11.2023 published: Print-Electronic CommentIn: Int J Infect Dis. 2020 Oct;99:38-39. - PMID 32738483 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2020.06.099 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312007930 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312007930 | ||
| 003 | DE-627 | ||
| 005 | 20231225143500.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2020.06.099 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1039.xml |
| 035 | |a (DE-627)NLM312007930 | ||
| 035 | |a (NLM)32623082 | ||
| 035 | |a (PII)S1201-9712(20)30534-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arshad, Samia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.07.2020 | ||
| 500 | |a Date Revised 11.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Int J Infect Dis. 2020 Oct;99:38-39. - PMID 32738483 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a SIGNIFICANCE: The United States is in an acceleration phase of the COVID-19 pandemic. Currently there is no known effective therapy or vaccine for treatment of SARS-CoV-2, highlighting urgency around identifying effective therapies | ||
| 520 | |a OBJECTIVE: The purpose of this study was to evaluate the role of hydroxychloroquine therapy alone and in combination with azithromycin in hospitalized patients positive for COVID-19 | ||
| 520 | |a DESIGN: Multi-center retrospective observational study | ||
| 520 | |a SETTING: The Henry Ford Health System (HFHS) in Southeast Michigan: large six hospital integrated health system; the largest of hospitals is an 802-bed quaternary academic teaching hospital in urban Detroit, Michigan | ||
| 520 | |a PARTICIPANTS: Consecutive patients hospitalized with a COVID-related admission in the health system from March 10, 2020 to May 2, 2020 were included. Only the first admission was included for patients with multiple admissions. All patients evaluated were 18 years of age and older and were treated as inpatients for at least 48h unless expired within 24h | ||
| 520 | |a EXPOSURE: Receipt of hydroxychloroquine alone, hydroxychloroquine in combination with azithromycin, azithromycin alone, or neither | ||
| 520 | |a MAIN OUTCOME: The primary outcome was in-hospital mortality | ||
| 520 | |a RESULTS: Of 2,541 patients, with a median total hospitalization time of 6 days (IQR: 4-10 days), median age was 64 years (IQR:53-76 years), 51% male, 56% African American, with median time to follow-up of 28.5 days (IQR:3-53). Overall in-hospital mortality was 18.1% (95% CI:16.6%-19.7%); by treatment: hydroxychloroquine+azithromycin, 157/783 (20.1% [95% CI: 17.3%-23.0%]), hydroxychloroquine alone, 162/1202 (13.5% [95% CI: 11.6%-15.5%]), azithromycin alone, 33/147 (22.4% [95% CI: 16.0%-30.1%]), and neither drug, 108/409 (26.4% [95% CI: 22.2%-31.0%]). Primary cause of mortality was respiratory failure (88%); no patient had documented torsades de pointes. From Cox regression modeling, predictors of mortality were age>65 years (HR:2.6 [95% CI:1.9-3.3]), white race (HR:1.7 [95% CI:1.4-2.1]), CKD (HR:1.7 [95%CI:1.4-2.1]), reduced O2 saturation level on admission (HR:1.5 [95%CI:1.1-2.1]), and ventilator use during admission (HR: 2.2 [95%CI:1.4-3.3]). Hydroxychloroquine provided a 66% hazard ratio reduction, and hydroxychloroquine+azithromycin 71% compared to neither treatment (p<0.001) | ||
| 520 | |a CONCLUSIONS AND RELEVANCE: In this multi-hospital assessment, when controlling for COVID-19 risk factors, treatment with hydroxychloroquine alone and in combination with azithromycin was associated with reduction in COVID-19 associated mortality. Prospective trials are needed to examine this impact | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a Hydroxychloroquine | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a SARS-COV-2 | |
| 650 | 4 | |a Therapy | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Azithromycin |2 NLM | |
| 650 | 7 | |a 83905-01-5 |2 NLM | |
| 700 | 1 | |a Kilgore, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Chaudhry, Zohra S |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobsen, Gordon |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Dee Dee |e verfasserin |4 aut | |
| 700 | 1 | |a Huitsing, Kylie |e verfasserin |4 aut | |
| 700 | 1 | |a Brar, Indira |e verfasserin |4 aut | |
| 700 | 1 | |a Alangaden, George J |e verfasserin |4 aut | |
| 700 | 1 | |a Ramesh, Mayur S |e verfasserin |4 aut | |
| 700 | 1 | |a McKinnon, John E |e verfasserin |4 aut | |
| 700 | 1 | |a O'Neill, William |e verfasserin |4 aut | |
| 700 | 1 | |a Zervos, Marcus |e verfasserin |4 aut | |
| 700 | 0 | |a Henry Ford COVID-19 Task Force |e verfasserin |4 aut | |
| 700 | 1 | |a Nauriyal, Varidhi |e investigator |4 oth | |
| 700 | 1 | |a Hamed, Asif Abdul |e investigator |4 oth | |
| 700 | 1 | |a Nadeem, Owais |e investigator |4 oth | |
| 700 | 1 | |a Swiderek, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Godfrey, Amanda |e investigator |4 oth | |
| 700 | 1 | |a Jennings, Jeffrey |e investigator |4 oth | |
| 700 | 1 | |a Gardner-Gray, Jayna |e investigator |4 oth | |
| 700 | 1 | |a Ackerman, Adam M |e investigator |4 oth | |
| 700 | 1 | |a Lezotte, Jonathan |e investigator |4 oth | |
| 700 | 1 | |a Ruhala, Joseph |e investigator |4 oth | |
| 700 | 1 | |a Fadel, Raef |e investigator |4 oth | |
| 700 | 1 | |a Vahia, Amit |e investigator |4 oth | |
| 700 | 1 | |a Gudipati, Smitha |e investigator |4 oth | |
| 700 | 1 | |a Parraga, Tommy |e investigator |4 oth | |
| 700 | 1 | |a Shallal, Anita |e investigator |4 oth | |
| 700 | 1 | |a Maki, Gina |e investigator |4 oth | |
| 700 | 1 | |a Tariq, Zain |e investigator |4 oth | |
| 700 | 1 | |a Suleyman, Geehan |e investigator |4 oth | |
| 700 | 1 | |a Yared, Nicholas |e investigator |4 oth | |
| 700 | 1 | |a Herc, Erica |e investigator |4 oth | |
| 700 | 1 | |a Williams, Johnathan |e investigator |4 oth | |
| 700 | 1 | |a Lanfranco, Odaliz Abreu |e investigator |4 oth | |
| 700 | 1 | |a Bhargava, Pallavi |e investigator |4 oth | |
| 700 | 1 | |a Reyes, Katherine |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 97(2020) vom: 01. Aug., Seite 396-403 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:97 |g year:2020 |g day:01 |g month:08 |g pages:396-403 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2020.06.099 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 97 |j 2020 |b 01 |c 08 |h 396-403 | ||